Difference between revisions of "Part:BBa K3885222"

(→‎Characterization)
(→‎Characterization)
Line 25: Line 25:
 
<div style="border: 1px solid #000; width: 30%">
 
<div style="border: 1px solid #000; width: 30%">
 
<img src="https://static.igem.org/mediawiki/parts/b/b6/222_EMSA.png" width="150" style="display: block;margin: 10px auto;"/>
 
<img src="https://static.igem.org/mediawiki/parts/b/b6/222_EMSA.png" width="150" style="display: block;margin: 10px auto;"/>
 +
 +
[[
 +
<center>'''Figure 1: BsaI digestions'''</center>
 
<p style="text-align: center;">
 
<p style="text-align: center;">
 
Figure 2. Polyacrylamide gel-shift assay analysis of the igRNA hybridizating with CXCL9 mRNA.  
 
Figure 2. Polyacrylamide gel-shift assay analysis of the igRNA hybridizating with CXCL9 mRNA.  
 
  </p>
 
  </p>
 +
]]
 
</div>
 
</div>
 
</div>
 
</div>

Revision as of 18:31, 17 October 2021


J23119-CXCL9

The short version of DNA sequence coding for CXCL9 mRNA can be expressed under the control of a strong promoter J23119.

Usage and Biology

1.This plamsid can transfer CXCL9 mRNA. CXCL9 mRNA is a biomarker, based on the final intensity of the fluorescence, we can know if a person is sick.
2.It can be used in other experiments for disease markers.

Characterization

[[
'''Figure 1: BsaI digestions'''

Figure 2. Polyacrylamide gel-shift assay analysis of the igRNA hybridizating with CXCL9 mRNA.

]]



It can transfer CXCL9 mRNA to combine with the complex of igRNA and Cas9 protein. Then they can perform cutting function. And they can cut tetR of P70-σ28-P28-tetR to express fluorescence of P28-tetO-deGFP.We know from experiments that the dCas9-igRNA complex which combined with CXCL9 has higher fluorescence intensity.

Design Page

CXCL9 mRNA, a biomarker indicative of rejection in renal-transplant recipients. We found that existing techniques for detecting rejection in kidney transplantation can not be used to detect disease in a non-invasive manner. And CRISPR-Cas has the potential to detect disease.So we use CRISPR-Cas9 to verify if this system can detect CXCL9 mRNA or other biomarkers.

References

Kaminski Michael M et al. A CRISPR-based assay for the detection of opportunistic infections post-transplantation and for the monitoring of transplant rejection.[J]. Nature biomedical engineering, 2020, 4(6) : 601-609.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal NheI site found at 7
    Illegal NheI site found at 30
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]